OncoMatch/Clinical Trials/NCT05272826
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Is NCT05272826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Iberdomide and Bortezomib for multiple myeloma.
Treatment: Iberdomide · Bortezomib · Dexamethasone · Isatuximab — This study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anti-myeloma therapy
Exception: does not include radiotherapy, bisphosphonates, or a single short course of steroid (≤ dexamethasone 40 mg/day for 4 days; not within 14 days of treatment start)
Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [i.e. less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of treatment start])
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L; Platelet count ≥ 50 x 10^9/L; Hemoglobin ≥ 80 g/L
Kidney function
Creatinine clearance ≥ 30 mL/min either directly measured via 24-hour urine collection or calculated using MDRD
Liver function
Serum AST and ALT ≤ 1.5 x upper limit of normal (ULN)
Cardiac function
QTc interval < 470 msecs (QTcF); no evidence of current clinically significant uncontrolled arrhythmias; no history of MI, acute coronary syndromes, coronary angioplasty, stenting or bypass grafting within six months; no class III or IV heart failure (NYHA); no uncontrolled hypertension
Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L. Serum AST and ALT ≤ 1.5 x upper limit of normal (ULN). Creatinine clearance ≥ 30 mL/min...Platelet count ≥ 50 x 10^9/L...Hemoglobin ≥ 80 g/L...QTc interval ≥ 470 msecs...NYHA heart failure class III-IV...uncontrolled hypertension
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05272826 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages